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CASE REPORT
Fixed Drug Eruption Due to Allopurinol: Positive Oral 
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Hyun Jong Lee, M.D., Hei Sung Kim, M.D., Young Min Park, M.D., Hyung Ok Kim, M.D., 
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Department of Dermatology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
A fixed drug eruption (FDE) is characterized by the presence 
of a solitary or multiple, pruritic, well-circumscribed, erythe-
matous plaques. These lesions have tendency to recur at 
same sites and heal with residual hyperpigmenation. With 
repeated attacks, the size and/or number of the lesions may 
increase. So far, more than 100 drugs have been implicated 
in causing FDEs, including ibuprofen, sulfonamide, napro-
xen, and tetracylines. FDE caused by allopurinol has been 
rarely reported in the literature, but there has been no 
confirmed case based on oral provocation test. Herein, we 
report a case of FDE in which the lesions recurred whenever 
allopurinol was administered for the treatment of gout. A 
64-year-old male experienced repeated episodes of well- 
demarcated dusky erythematous patches on the whole body 
for 2 months. He took allopurinol intermittently for amelio-
ration of his gout symptom, but denied other medication 
history. Pruritic erythematous edema developed on the 
previous lesions 12 hours after oral provocation of 200 mg of 
allopurinol. (Ann Dermatol 23(S3) S402∼S403, 2011)
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INTRODUCTION
A fixed drug eruption (FDE) is characterized by a solitary 
or multiple, pruritic, well circumscribed, erythematous pla-
ques. These lesions have tendency to recur at same sites 
and heal with residual hyperpigmenation. With repeated 
attacks, the size and/or number of the lesions may increase.
More than 100 drugs have been implicated as causes of 
FDEs, including ibuprofen, sulfonamide, naproxen, and 
tetracyclines. FDE caused by allopurinol is a rare occur-
rence, and no confirmed case has been reported on the 
basis of oral provocation test. We herein report a case of 
FDE following the administration of allopurinol for the 
treatment of gout.
CASE REPORT
A 64-year-old man visited our clinic with complaints of 
recurrent, dusky, erythematous macules on the hands, 
elbow, perioral area and right thigh (Fig. 1A). The patient 
stated that he had a previous history of a similar lesion on 
several occasions at the same site after consuming alco-
hol. The patient had occasionally taken allopurinol for 
treatment of acute gout attack, which was usually follo-
wed by drinking. The patient had experienced skin lesions 
while taking allopurinol, which resolved when drug was 
withdrawn and recurred in the same location when the 
drug was re-administered.
The lesions cleared within 7 days of treatment with sys-
temic and topical corticosteroid, leaving slight hyperpig-
mentation. Topical provocation test was performed 2 
weeks after resolution of the skin lesions, in the absence 
of therapy. Allopurinol, in the crushed and dispersed form 
for patch testing was applied at a concentration of 10% in 
petrolatum base at the site of previous lesion. Readings 
were carried out immediately and 2 days after provoca-Fixed Drug Eruption Due to Allopurinol: Positive Oral Provocation
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Fig. 1. Clinical appearance of the fixed drug eruption on the
patient’s trunk (A) at the time of the 1st visit and (B) 12 hours
after an oral provocation test with allopurinol.
tion, where the results were negative. 
Two weeks after the patch test, we decided to perform an 
oral provocation with allopurinol. We started to admini-
ster a quadrant therapeutic dose of allopurinol (100 mg) 
with no response. A day afterwards, half the therapeutic 
dose of allopurinol (200 mg) was administered. Twelve 
hours after exposure to allopurinol, a flare-up of the FDE 
occurred, with development of erythema at the previously 
affected site. Pruritic, erythematous, edematous patches 
developed on sites of the previous lesion after oral provo-
cation with 200 mg of allopurinol (Fig. 1B). From the 
findings, we were able to confirm the role of allopurinol 
as a cause of FDE in our case.
DISCUSSION
FDE can develop from 30 minutes to 8 to 16 hours after 
ingestion of medications. Lesion may occur on any site on 
the skin and mucosa. However, preferential sites for invol-
vement in the formation of FDE have been reported for 
certain drugs.
Allopurinol is rarely a cause of FDE. Dermatologic adverse 
drug reactions due to allopurinol are usually maculopapu-
lar eruptions, but severe cutaneous adverse drug reactions 
such as drug hypersensitivity syndrome, Stevens-Johnson 
syndrome and toxic epidermal necrolysis can also occur. 
In rare instances, allopurinol has been reported to cause 
eosinophilic pustular folliculitis, toxic pustuloderma, gra-
nuloma annulare disseminatum and a pityriasis rosea-like 
adverse reaction
1. 
The pathogenesis of the FDE still remains to be obscure. It 
seems that a large homogenous population of CD8＋ T 
cells are distributed along the epidermal basal layer in 
FDE and possess the capacity to produce large amounts of 
IFN-r. These cells are likely to play a significant role in the 
formation of FDE lesions. Same-site recurrence may be 
explained with respect to immunohistochemical findings 
of prolonged ICAM-1 expression in the lesional kerati-
nocytes, which correlate with the degree of residing epi-
dermal T suppressor/cytotoxic cells
2.
Identification of the causative drugs of FDE is usually 
established by re-challenge, but patch tests may be a safer 
alternative
3. The re-challenge test seems to represent the 
most reliable method for identifying causative drugs, even 
though it is not 100% reliable and probably hazardous. 
Systemic oral challenge and topical provocation tests are 
usually performed to identify the drugs responsible for the 
FDE. Oral challenge tests with a single therapeutic dose of 
the suspected drug, starting at 1/10∼1/2 of the therapeu-
tic dose followed by full therapeutic dose on the subse-
quent day if there is no reaction to the first dose, is the 
usually followed protocol
4.
There are several causes for the appearance of false 
negative results in topical provocation test. First and most 
importantly, patch test should be done at sites of previous 
lesions because patch tests at the non-lesional sites usually 
yield a negative response. Other responsible factors are 
the timing of patch testing, concentrations and penetration 
properties of the drug
5.
We performed topical provocation 3 weeks after the last 
attack. We assumed that this was a refractory period, 
which resulted in no provocation. Based on our past 
experience, we recommend topical provocation to be 
performed at least 2 weeks after resolution of the lesions. 
Allopurinol is the first-choice drug for maintenance of 
gout patients and at the same time, the only possible 
medication. Therefore, we suggest allopurinol desensitiza-
tion for patients who have FDE to allopurinol.
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